NCT00782821View on ClinicalTrials.gov

Randomized Trial of Induction Therapies in High Immunological Risk Kidney Transplant Recipients

PHASE4CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 30, 2008

Primary Completion Date

February 28, 2013

Study Completion Date

March 31, 2013

Conditions
Kidney Transplantation
Interventions
DRUG

Rabbit Antithymocyte Globulin

rATG will be given 1.5mg/kg intravenous (IV) per dose.

DRUG

Velcade

Velcade will be given 1.3mg/m2 via intravenous push (IVP) per dose.

DRUG

Rituxan

Given via IV per group assignment.

Trial Locations (2)

45202

The Christ Hospital, Cincinnati

45219

The University Hospital, Cincinnati

Sponsors
All Listed Sponsors
collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

collaborator

Genzyme, a Sanofi Company

INDUSTRY

lead

University of Cincinnati

OTHER